Independent research conducted at the University of Wisconsin-Madison on Helius Medical Technologies’ (NASDAQ:HSDT; TSX:HSM) translingual neurostimulation for the treatment of chronic symptoms due to mild-to-moderate traumatic brain injury (mmTBI) were published in the December 2019 issue of the peer-reviewed Archives of Rehabilitation Research and Clinical Translation.
The newly published results from the double-blind randomized clinical trial, which paired translingual neurostimulation using the Portable Neuromodulation Stimulator (PoNS) device with therapeutic activities, showed significantly improved balance and gait scores over the 14-week treatment period and the outcomes were sustained for 12 weeks after discontinuing the treatment.
“Traumatic brain injuries are rising steadily in North America and whether these injuries are mild or moderate, the effects can last a lifetime,” Philippe Deschamps, CEO of Helius, said in a statement.
“The results from this independent clinical trial provide clinical support for the PoNS Treatment as an effective treatment option for patients suffering from the effects of mmTBI and we are excited to have the validation of the data in a peer reviewed publication,” he added.
PoNS Treatment is exclusively offered by authorized clinics, with multiple locations across Canada.
The research article can be viewed here.
